News

Novo Nordisk rode Ozempic’s success to becoming Europe’s top company. Now it’s faltering and its CEO is out.
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its ...
Ozempic-Maker CEO Ousted Over Pharma Company’s Rocky Market Downturn
In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...
Novo Nordisk ousts boss as Ozempic maker battles slump
Novo Nordisk has announced that chief executive Lars Fruergaard Jørgensen will step down just days after the pioneering maker of obesity drugs cut its profit forecast. The Danish group said on Friday ...
Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
Novo Nordisk CEO Lars Fruergaard Jorgensen to resign as Ozempic faces stiff competition
The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down, the ...
Zacks Investment Research on MSN3d
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
Ignore The Noise - Novo Nordisk Is A Clear Buy
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...